1. Introduction
Live animal models of penetrating neurotrauma involve some of the most invasive procedures in experimental biology, with profound neurological deficits induced (hemiplegia, quadriplegia, bladder dysfunction and infection risk) [
1,
2]. The models require extensive training, infrastructure, regulatory licenses and facilities for pre/post-operative care. Induction of injuries can be variable across groups, and do not allow for reliable statistical comparisons across groups without large animal numbers. For developmental screening applications, such invasive models present significant ethical dilemmas, with public opinion warranting that alternative approaches be developed to reduce reliance on animal testing [
3]. Pathology-mimetic and higher-throughput alternatives are urgently needed for biological testing, in line with the global drive for Reduction, Refinement and Replacement (3R’s) of animal research.
Despite this high need, in vitro alternatives to live animal neurological models are generally overly simplistic, lacking the multicellular brain cell network found in vivo, and usually lack an immune (microglial) component, or complex neuronal network, although protocols are under development to add in microglia using additional culturing steps. Accordingly, they are unable to mimic cardinal pathological features of neurological injury or be used to study post-injury regeneration. In vitro models range in complexity from the simplest, two-dimensional (2D) monolayer cell cultures to the highly complex three-dimensional (3D) organotypic slice or organoid cultures. Different models have specific associated features which determine their research utility in biomaterials research, e.g., pathological relevance, technical difficulty and ease of maintenance [
4]. Organotypic slice (OTS) cultures represent a transitional system that preserves the original tissue, and its inherent structural architecture, combining benefits of in vivo and in vitro cell culture models. An advantage of this approach is that it permits therapeutic agents/biomaterials, stimuli or mechanical/chemical injury to be applied directly to the slice at any stage of cultivation. These offer a moderate-throughput platform to simultaneously monitor parameters of neural regeneration (i.e., nerve fibre outgrowth, glial scar formation, remyelination and immune cell activation) in response to various injury mechanisms and therapeutic approaches [
5].
Alternatively, there has been a large focus on human iPSCs to generate neural cells in 2D in vitro culture, including in combination with microfluidic culturing systems to generate brain-on-a-chip modelling systems resembling tissue-like physiology [
6]. These systems are generally low-throughput and time-consuming with limitations to their scalability and lack cellular maturity within the models. Human cell-derived CNS organoids are another complex in vitro modelling contender, which have potential for molecular/structural mimicry of CNS tissues. CNS organoids are stem cell-derived self-organising suspension cultures with major neural cell types (generally excluding microglia) and cytoarchitectures recapitulating developing tissues [
7]. Self-organising approaches allow for the formation of a “mini-brain” displaying multiple regions of neural tissue comparable to the human brain [
8] with integration into organoid “assembloids” through fusion of separate organoid types to generate complex systems. In terms of recapitulating traumatic injury, organoid techniques do not provide an accessible platform for physical manipulation due to their free-floating nature. However, one group in 2020 developed a mechanism of traumatic injury to brain organoids through high-intensity focused ultrasound [
9].
Hydrogel-based polymeric biomaterials have emerged as a major platform to mimic the extracellular matrix of soft tissues for the development of 3D CNS-like tissue models, as their high porosity allows free movement of fluid and nutrients for 3D cell growth. Hydrogels can be modulated to match the endogenous tissue stiffness of neural tissues (which can vary by anatomical region (3–10 kPa)) [
10] following injury. Cell-encapsulating hydrogels have the potential to be adapted for development of high-throughput modelling systems with technical ease whilst offering complex in vivo-like cellular dynamics. Despite this, few studies have used hydrogels for growth of complex neural cell networks within which to simulate neural trauma.
Here, we have deployed a collagen-based hydrogel matrix to demonstrate that:
- (a)
growth of a complex multicellular neural network can be achieved within the polymer substrate;
- (b)
a focal area of trauma can be reliably and reproducibly induced in the construct;
- (c)
complex injury pathology can be simulated; and
- (d)
the model can support therapeutic testing, by implanting a surgical grade biomaterial into the lesion focus.
Based on our findings, we propose that this new approach can be used as a high-throughput 3D injury model to evaluate neural cell responses to introduced therapeutics.
3. Discussion
The data presented here demonstrate that it is feasible to develop a dense network of five major brain cell populations within a soft polymer matrix, in order to develop a neuromimetic brain tissue plug. We also show that a localised, highly reproducible traumatic injury can be created in this neuro-construct. The results demonstrate a functioning 3D injury model within which stereotypical injury responses (seen in vivo following traumatic injury) can be induced. To our knowledge, this is the first time these key cellular pathological responses have been reported within a 3D neural construct model. Key observations post-injury are as follows: induction of a glial cell scar (a known barrier to axonal regeneration) with elevated GFAP expression; induction of amoeboid microglial phenotypes indicative of activation and bipolar, potentially migratory OPC profiles at the lesion margins (as reported in vivo following traumatic brain injury) [
11]. Imaging of the axonal network around the injury site proved to be challenging; however, in proof-of-concept studies, axons tended to grow around the injury rather than towards it, suggesting a barrier to regeneration; we can speculate due to the glial scar. Critically, we were able to show that a mouldable biomaterial (surgical-grade dural sealant Duragen Plus
TM) could be introduced into the lesion cavity, to simulate biomaterial implantation in vivo, with extensive cellular infiltration by microglia.
In terms of traumatic brain injury models, Liaudanskaya, et al. (2020) [
12] reported a controlled impact study on a brain-like tissue model of a 3D cortical neuronal culture through an established impact device. Other studies have involved calcium-dependent injury and oxygen/glucose-deprivation injury on 3D constructs of primary human NSCs [
13] or the use of a compression device on cortical neuronal 3D hydrogels [
14]. We are not aware of similar studies investigating penetrating traumatic brain injury in the 3D context, or induction of pathology and biomaterial interfacing with neural cell populations.
We believe the model offers a range of advantages versus current available in vitro neural model systems. Please note that while technologies such as human iPSCs and brain organoids have revolutionised neural cell models, we consider that our model offers several comparative advantages in terms of scalability, presence of immune cells, cellular maturity, accessibility and ease of injury induction/imaging, while also avoiding issues associated with core necrosis in dense 3D models [
15]. First, the dissociated tissue to develop the model is derived from primary cells which limits drawbacks associated with the widespread use of neural cancer cell lines (such as abnormal chromosomal number, cryptic contamination, aneuploidy and resistance to toxicity) [
16]. The cells are derived from postnatal mouse tissue, avoiding the sacrifice of breeding females to derive embryonic tissue. It offers a high degree of cellular complexity in order to mimic in vivo neural architecture and the interactions of multiple brain cell populations, including the native immune cells. Additionally, all cell types are derived simultaneously, from the same tissue, and are treated identically throughout the process, limiting variability associated with deriving cells from different sources. For example, in 2020 Raimondi et al. [
17] reported a 3D brain-like tissue model from primary cortical cells, wherein a co-culture of independently isolated glial cells and neuronal cells was carried out. This involves a time-consuming process to derive each cell type individually (e.g., 20 days to harvest astrocytes from a confluent flask). By contrast, we can achieve a complex neural network in approximately 7–20 days.
Second, a key feature of our model is in vitro simulation of cardinal neuropathological events in vivo, highlighting the utility of the model as a core approach to screen therapeutic interventions prior to in vivo testing. Focal injuries could be induced in a highly reproducible manner in terms of size/shape. Additionally, multiple injuries can be induced in the same construct, so several experimental replicates can be generated in parallel for multiple comparisons of control/test conditions. The model can also be adapted into a high-throughput format adaptable to different well formats and construct sizes. The 3D constructs are amenable to imaging using standard microscopy methods such as Z-stack imaging and confocal microscopy, and dynamic live cell imaging with quantification of cells and pathological responses feasible.
Third, we consider that the approach is highly versatile and can potentially be adopted in the future for a range of pathologies (e.g., contusion injuries or demyelination), anatomical areas (example cortex versus cerebellum), species (rodent including genetically modified species, induced pluripotent stem cells, large animals and human tissue), tissue ages (to simulate neonatal versus adult tissue and pathology), different polymers for encapsulation (to study the effects of tailored biomaterials on neural cell development) and biomaterial implantation (for screening of a range of nanomaterials and biomaterials). Polymer concentrations can be adjusted so as to mimic human brain tissue stiffness, to create a more physiologically relevant system versus free floating models or cells grown on “hard” substrates (e.g., glass). For example, we previously reported that collagen gels with a similar concentration to this study (0.6–1.2%) had stiffnesses ranging from 34 to 150 Pa [
18], which is similar to the stiffness of embryonic brain. This is important as it is increasingly recognised that substrate stiffness can critically impact cell fate and development, so stiffness matching to host tissue is critical; as an example, neurons show greater elongation on soft substrates [
19]. Additionally, elegant studies have demonstrated that stiffness of injured neural tissue differs from that of normal tissue [
20]. Our model offers the capacity to tune the polymer stiffness to mimic such variables. It is noteworthy that the cellular proportions established within the soft, 3D constructs differed from those in a 3D network on a hard substrate (3D: astrocytes: 25.97 ± 3.1%, neurons: 45% estimated, oligodendrocytes: 10.7 ± 0.85%, microglia: 4.77 ± 0.69% and OPCs: 12.5 ± 1.48% versus 2D: astrocytes: 35.3 ± 0.2%, neurons: 45.8 ± 2.1%, oligodendrocytes: 2.73 ± 0.17%, microglia: 10.35 ± 3.89%, OPCs: 11.15 ± 0.32%), suggesting an influence on cell fate [
21].
Finally, the model is technically easy to develop and monitor, scalable and very cost effective compared to live animal experiments. In our experience, users can be rapidly trained (2–3 weeks), making it accessible to users across the world, including low–middle-income countries, without requiring special regulatory permissions e.g., from the Home Office. Accordingly, we believe that this approach can offer a valuable new tool for neurobiology research and the development of neurotherapeutics.
In the future, it would be valuable to establish if clinical imaging techniques, such as magnetic resonance imaging or magnetic resonance spectroscopy, can be used to monitor and study pathology in situ. The development of 3D multielectrode arrays (for example, containing pillars with embedded electrodes [
22] for electrophysiological readouts from the tissue plug) would also provide valuable functional readouts for real-time multimodal monitoring of the constructs, in parallel with the ability to monitor cellular pathology using histological assays.
While NG2+ OPCs maintained their multi-processed morphologies and ramified Iba1+ microglia were expressed in distinct patches (albeit at lower numbers than the 2D model), a striking observation was the alteration in astrocytic phenotypes compared with cells on 2D glass substrates. It is not clear what accounts for this observation. Astrocytes are known to remodel their environment [
23], and it is feasible that the process is associated with dramatic alterations in their morphologies. It will be of high value to carry out detailed genomic/proteomic profiling of the polymer-encapsulated cells to (a) understand and quantify the difference in gene/protein expressions which could contribute to altered cell fate and (b) to compare these with in vivo gene expression (to study if 3D models in soft substrates can more closely mimic in vivo neural microenvironments) versus standard neural cell culture on hard substrates. Whilst it was out of the scope of this study, future experiments may also attempt to study the complex cell–cell interactions which are known to influence ongoing pathological response in neural injury [
24]. Our system may offer a simpler format to achieve this than in vivo models where spatiotemporal resolution of cell behaviour is much harder to achieve.
5. Materials and Methods
5.1. Materials
Culture plastics and media were from Thermo Fisher Scientific (Loughborough, UK) or Scientific Laboratory Supplies (SLS, Nottingham, UK), unless stated otherwise. Vectashield mounting medium containing 4′,6-diamidino-2-phenylindole (DAPI) was from Vector Laboratories, UK. Duragen Plus™ matrix (medically approved, neurosurgical-grade biomaterial derived from Type I bovine collagen) was from Integra LifeSciences, Princeton, NJ, USA.
5.2. Antibodies
Primary antibodies were rabbit anti-glial fibrillary acidic protein (GFAP), from DakoCytomation, (Ely, UK), goat anti-ionised calcium-binding adapter molecule 1 (Iba1) from Thermo Fisher Scientific (Loughborough, UK), mouse anti-nerve/glial antigen 2 (NG2) and rat anti-Myelin Basic Protein (MBP) from Millipore (Danvers, MA, USA), mouse anti-beta-III-tubulin (Tuj1) from Biolegend (San Diego, CA, USA). Secondary antibodies were fluorescein isothiocyanate (FITC)-conjugated donkey anti-mouse, -rabbit, -goat; cyanine 3 (Cy3)-conjugated donkey anti-mouse, -goat, -rat; cyanine 5 (Cy5)-conjugated donkey anti-mouse and -rabbit from Stratech Scientific (Suffolk, UK).
5.3. Preparation of Mixed Cortical Brain Cell Cultures
Fresh tissues were dissected from mouse pups (CD1), with litters ranging from 8 to 12 pups. Keele University retains Home Office licensed authority, as a designated premises, providing regulatory compliance for the care and welfare of the animals used in this study [Keele University Establishment licence number: X350251A8 (copy available on request)]. Ethical approval for the schedule 1 usage of animals used in this study was obtained from Keele University Animal Welfare and Ethical Review Body in 2017. Mice maintaining specified pathogen-free health status were housed and bred in the Keele Biological Service Unit, in accordance with the Code of Practice for the Housing and Care of Animals Bred, Supplied or Used for Scientific Purposes. Litters were maintained on a continuous 12:12 light cycle, 22.5 ± 0.4 °C, 46% ± 5% humidity. Mice were bred and maintained according to the UK Code of Practice for the housing and care of animals used for scientific procedures, Animals (Scientific Procedures) Act 1986. Pups of both sexes were used in the study and culled via the schedule 1 method of an overdose of anaesthetic, sodium pentobarbital (Animalcare Ltd., York, UK), 1 mL/kg intraperitoneal injection, on post-natal day 1–4, weight ca 2.5–3.5 g.
Brains were dissected and transferred to dissection medium (2.5% HEPES in Earl’s balanced salt solution) on ice. Under laminar flow, cerebral cortices were isolated by removing the olfactory bulbs, hindbrain, and subcortical tissue. Cortical rolling on sterile paper removed the meninges and blood vessels. Cortices were minced with a scalpel and pelleted at 1200 rpm for 5 min, then resuspended in dissection medium to cover the pellet. Then, 0.25 mL of DNase and 0.5 mL Trypsin-EDTA was added to every 4 brains dissected. The cells were then shaken at 37 °C for 20 min at 150 rpm. Cells were gently triturated to further break any tissue aggregates by a P1000 (without frothing), and 2 mL of fetal bovine serum added to stop cell-trypsinisation. 2 mL of neurobasal medium (96% Neurobasal A (48 mL), 2 mM Glutamax-I (0.5 mL), 2% B27 (1 mL), 50 μg mL−1 penicillin, and 50 μg mL−1 streptomycin (0.5 mL) was used to triturate the cells (×30), which were then pelleted at 1200 rpm for 3 min, resuspended in 2 mL of neurobasal medium and filtered into 50 mL tubes using 70 μm then 40 μm cell strainers, with rinsing using neurobasal medium. The resulting cell stock was diluted in trypan blue (1:5), which can pass through the membrane of dead cells, dyeing the cytoplasm blue, while it does not stain live cells. The solution was added to a hemocytometer and a manual count of the live and dead cells was completed on a microscope. All further calculations were performed based on the number of viable cells observed.
5.4. Construction of 3D Cellular Hydrogels
Gel formulation was adapted from Adams et al., 2016 [
18]. For the cellular 3D gels, the enzymatically dissociated cortical dissociate was incorporated into the collagen solution prior to setting, allowing cortical cells to be encapsulated within the collagen fibres as part of a 3D network. Gels were set in 24 well plates on top of glass coverslips treated with EtOH (5 min), washed with water and left to air dry. The coverslips were found to facilitate the removal of gels from the wells. Final seeding densities of 2.5 × 10
7 cells/mL with collagen concentrations of 1 mg/mL were used to establish the gels. To generate certain collagen concentrations within the gel, a set of formulae were used to calculate volumes of each reagent [
18]. Firstly, the collagen was dissolved in acetic acid to the required concentration, then 10 × MEMα solution was added. Subsequently, the appropriate volume of cells was added, which needs to be immediately titrated throughout the solution or it can cause aggregations. Lastly, the solution was neutralised with NaOH, and this was added drop wise whilst at the same time swirling the mixture until the pH indicator (within the MEMα) turns from yellow to pink. All components were always kept on ice to ensure the gel did not set before seeding into wells. Then, 200 µL of the gel solution was added to sterile glass coverslips, which forms a button shape. Once seeded, plates were transferred carefully to the incubator for 30–60 min. Following gelation, 500 μL of complete neurobasal medium was added to each well. The gel medium was topped up to 1 mL after 2 days and had a 50% medium change every 3–4 days.
5.5. Introducing an Injury into the 3D Cellular Gels
Once the gels had been in culture for a minimum of 7 days, a network of cells could be visualised under light microscopy. The injury was made when gels appeared relatively confluent with cellular processes extending in most fields of focus. The tip end of a P1000 pipette tip was used to puncture through the gel then twisted clockwise and anticlockwise several times until the gel was completely cut. The waste gel was held inside the pipette tip end and removed. This was carried out 3 times to create 3 separate lesions within the same 3D cellular gel culture.
5.6. Implantation of a Biomaterial Within the Injury Site of the Gels
DuraGenTM (Integra LifeSciences, Princeton, NJ, USA) was cut to 900 µm wide strips by the tissue chopper, then each strip was cut to size with a scalpel to fit the injury within the gel. The medium was removed, and the soaked material was implanted into the injury area using forceps; the wells were then refilled with 2 mL of medium (the material expands to fill the injury once medium added).
5.7. Fixing and Staining the Gels
At appropriate timepoints, gels were fixed with 4% PFA for 30 min. Post-fixation, the PFA was removed, and the gels were washed 3 times with PBS (10 min per wash). The gels were blocked for an hour with 5% normal donkey serum with 0.3% triton X-100 (Merck, Gillingham, UK) in PBS. See
Section 5.2 for details of antibody suppliers. Primary antibodies chosen to stain for the 5 major cell types encapsulated in the gels were the following: mouse anti-Tuj1 (1:1000 in blocking solution) for neurons, rabbit anti-GFAP (1:500) for astrocytes, rabbit anti-Iba1 (1:200) for microglia, rabbit anti-Ng2 (1:200) for OPCs and rat anti-MBP (1:200) for oligodendrocytes. The primary antibody solutions were applied for 2 days at 4 °C. The gels then underwent 3 × 1 h washing steps in PBS. Following this, gels were incubated with the secondary antibodies which corresponded to the primary antibodies selected (FITC-conjugated donkey anti-mouse, -rabbit, -goat; Cy3-conjugated donkey anti-mouse, -goat, -rat and Cy5) conjugated donkey anti-mouse and –rabbit; 1:200 in blocking solution) with 2 µL/mL of DAPI for 6 h at RT and then washed 3 times at 1 h per wash with PBS. Subsequently, gels were mounted on glass slides with mounting medium (no DAPI).
5.8. 3D Culture Analyses
Fluorescence imaging and z-stack imaging of the gels was carried out on the Zeiss, Axioscope A1 microscope with an AxioCam ICc1 digital camera processed with Axiovision software (v3.2) (Carl Zeiss Microimaging GmbH, Goettingen, Germany). Quantitative analysis was performed using an Axio Observer.Z1 equipped with an AxioCam MRm powered by Zen 2 (blue edition) software (Carl Zeiss MicroImaging GmbH, Goettingen, Germany). All pathological responses to induced injuries were documented at 3 DPL.
5.9. Analysis of Cellular Distribution
Cells immuno-positive for Tuj-1, GFAP, Iba1, NG2 or MBP were quantified from respective fluorescent micrographs. Here, 5 regions per culture were selected using the DAPI-only channel on the fluorescent microscope; a minimum of 100 nuclei were assessed per condition. The percentages of each type were calculated by counting the proportion of cell marker-positive cells compared with total nuclei within the field.
5.10. Astrocyte Morphology and Analysis of Astrogliosis
Astrocyte morphologies were separated into 3 categories: finely processed astrocytes with small central soma (type 2 astrocyte), short-processed astrocytes with restricted processes and unprocessed astrocytes presenting as a spherical cell. The percent of each astrocyte morphology category was calculated for each condition.
To measure astrogliosis at the lesion site of the gels, the optical density of GFAP expression was evaluated. Firstly, fluorescent images were converted to 8-bit and inverted on ImageJ (v1.53) and the programme was calibrated for optical density. Next, using the freehand drawing tool, astrocytes at the lesion margins were traced and the overall optical density within the trace was calculated. A background optical density was also taken from an astrocyte-free area. The background OD was then subtracted from the OD of each astrocyte for that image. This was repeated for distal astrocytes over 400 µm from the lesion edge. The same exposure was used for imaging both lesional and distal areas of the gels. An average from each biological repeat was plotted for statistical analysis.
5.11. Analysis of Microglial Morphology
Microglial morphology within the 3D injury modelling system was characterised by a cell roundness index (CRI) [
27]. This can quantitatively describe the effect of the biomaterial on the morphology of the resident microglia, to determine their possible reactive state. Iba1 immunolabeled micrographs were imported into ImageJ. The relevant scale was set globally, and the freehand drawing tool function selected. Each Iba1+ve cell within the analysed areas was traced around and measured. Recorded measurements from each traced cell provides cell perimeter and area values. These values were then plugged into the equation for CRI: CRI = 4π × Area/perimeter
2; here the value of 1 denotes a complete circle, and towards 0 is ramified. It is important to note that since microglia were often distributed in patches throughout the gels, injuries did not always fall near or within a microglial patch. Though this rarely occurred, injuries without microglia nearby were not including within the quantification.
5.12. Statistical Analysis
All data are expressed as mean ± standard error of the mean (SEM). Data sets were analysed using Prism software (v5.0, GraphPad, USA). Note that n = number of constructs derived from independent litters of animals. A combination of unpaired two-tailed t-tests and one-way ANOVA statistical tests were employed and specified in the Results.